• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes
【24h】

Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes

机译：用于治疗2型糖尿病的皮下半蛋白质（NN9535）

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: It is critical for individuals with type 2 diabetes mellitus (T2DM) to maintain optimal glycemia while avoiding hypoglycemia, control body weight, and reduce cardiovascular risk. The GLP-1 receptor agonists stimulate glucose-dependent insulin release (low risk of hypoglycemia), inhibit glucagon secretion, slow gastric emptying and suppress appetite (weight loss). The new members of the class are available as once daily or weekly injections. Additionally, some members of the class have demonstrated reduced cardiovascular risk. Areas covered: This manuscript describes semaglutide-a new investigational long acting GLP-1 receptor agonist. The key trials from the clinical development process are reviewed and important end-points highlighted. Expert opinion: Once-weekly semaglutide has shown superiority in reducing glycosylated hemoglobin and body weight in comparison with placebo and active comparators when used as monotherapy or in combination treatment. In addition, semaglutide improved markers of ?cell function and have shown cardiovascular risk reduction similar to once daily liraglutide. Although, overall semaglutide safety was comparable to other GLP-1 receptor agonists (low risk of hypoglycemia and high frequency of gastrointestinal side effects), increase in retinopathy complications requires further investigation.
机译：简介：对于2型糖尿病（T2DM）的个体至关重要，以保持最佳的糖血症，同时避免低血糖，对照体重和降低心血管风险。 GLP-1受体激动剂刺激葡萄糖依赖性胰岛素释放（低血糖的风险低），抑制胰高血糖素分泌，慢胃排空，抑制食欲（减肥）。该类的新成员可以每日或每周注射提供一次。此外，班级的一些成员已经证明了心血管风险降低。所涵盖的区域：此稿件描述了Semaglutide-A新的调查长效GLP-1受体激动剂。审查临床发展过程的关键试验，并突出显示了重要的终点。专家意见：一旦使用作为单一疗法或组合治疗，与安慰剂和活性比较相比，每周一次半蛋白质在减少糖基化血红蛋白和体重时表现出优势。此外，Semagluterde改善了α细胞功能的标记，并显示出类似的心血管风险减少与一次日常平均Liraglutide相似。虽然，整体半蛋白质安全性与其他GLP-1受体激动剂（低血糖的风险低，胃肠道副作用的高频率），视网膜病变并发症的增加需要进一步调查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号